473
Views
8
CrossRef citations to date
0
Altmetric
Clinical Focus: Pain Management - Original Research

Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study

, , , &
Pages 32-39 | Received 29 Sep 2016, Accepted 14 Nov 2016, Published online: 05 Dec 2016

References

  • Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331–338. ​​​​​
  • Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273–281.
  • Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP task force on cancer pain. International Association for the Study of Pain. Pain. 1999;82(3):263–274.
  • Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81(1–2):129–134.
  • Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20(2):87–92.
  • Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18(3):177–183.
  • Portenoy RK, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag. 2010;6(2):97–108.
  • Williams JE, Yen JT, Parker G, et al. Prevalence of pain in head and neck cancer out-patients. J Laryngol Otol. 2010;124(7):767–773.
  • Caraceni A, Bertetto O, Labianca R, et al. Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI—Italian questionnaire for intense episodic pain. J Pain Symptom Manage. 2012;43(5):833–841.
  • Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain. 2006;7(8):583–591.
  • Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat Med. 2001;15(3):243–246.
  • Narayana A, Katz N, Shillington AC, et al. National Breakthrough Pain Study: prevalence, characteristics, and associations with health outcomes. Pain. 2015;156(2):252–259.
  • Mercadante S, Lazzari M, Reale C, et al. Italian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settings. Clin J Pain. 2015;31(3):214–221.
  • Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013;46(5):619–628.
  • Zeppetella G. Breakthrough pain in cancer patients. Clin Oncol (R Coll Radiol). 2011;23(6):393–398.
  • Elsner F, Zeppetella G, Porta-Sales J, et al. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. Clin Drug Investig. 2011;31(9):605–618.
  • Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–e68.
  • Simon SM, Schwartzberg LS. A review of rapid-onset opioids for breakthrough pain in patients with cancer. J Opioid Manag. 2014;10(3):207–215.
  • Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91(1–2):123–130.
  • Webster LR, Slevin KA, Narayana A, et al. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med. 2013;14(9):1332–1345.
  • Ashburn M, Slevin KA, Messina J, et al. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg. 2011;112(3):693–702.
  • Montague L, Green CR. Cancer and breakthrough pain’s impact on a diverse population. Pain Med. 2009;10(3):549–561.
  • Portenoy RK, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag. 2010;6(2):109–116.
  • Davies A, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15(7):756–763.
  • Bedard G, Hawley P, Zhang L, et al. A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer. 2013;21(9):2557–2563.
  • Raj SX, Thronaes M, Brunelli C, et al. A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. Support Care Cancer. 2014;22(7):1965–1971.
  • Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3(1):38–44.
  • Twomey F, O’Brien T, O’Reilly M, et al. An observational research study to evaluate the impact of breakthrough cancer pain on the daily lives and functional status of patients. Ir Med J. 2015;108(6):174–176.
  • Brief pain inventory (short form): MD Anderson Cancer Center. 1991 [updated 2013 Sep 24; cited 2016 Oct 31]. Available from: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/bpisf.pdf
  • Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89–95.
  • Ware J Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
  • Lowe B, Decker O, Muller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008;46(3):266–274.
  • Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284–1292.
  • Kessler RC, Barber C, Beck A, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003;45(2):156–174.
  • Kessler RC, Ames M, Hymel PA, et al. Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med. 2004;46(6 Suppl):S23–S37.
  • Ware JE Jr., Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33(4 Suppl):AS264–AS279.
  • Kongsgaard UE, Eeg M, Greisen H. The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study. Support Care Cancer. 2014;22(6):1655–1662.
  • Vellucci R, Fanelli G, Pannuti R, et al. What to do, and what not to do, when diagnosing and treating breakthrough cancer pain (BTcP): expert opinion. Drugs. 2016;76(3):315–330.
  • Katz N. Coxibs: evolving role in pain management. Semin Arthritis Rheum. 2002;32(3 Suppl 1):15–24.
  • Novotna S, Valentova K, Fricova J, et al. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. Clin Ther. 2014;36(3):357–367.
  • Davies A, Kleeberg UR, Jarosz J, et al. Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. Support Care Cancer. 2015;23(7):2135–2143.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.